Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar;3(1):53-66.
doi: 10.14218/JCTH.2014.00035. Epub 2015 Mar 15.

Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development

Affiliations
Review

Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development

Bénédicte Delire et al. J Clin Transl Hepatol. 2015 Mar.

Abstract

Liver fibrosis is part of the wound-healing response to liver damage of various origins and represents a major health problem. Although our understanding of the pathogenesis of liver fibrosis has grown considerably over the last 20 years, effective antifibrotic therapies are still lacking. The use of animal models is crucial for determining mechanisms underlying initiation, progression, and resolution of fibrosis and for developing novel therapies. To date, no animal model can recapitulate all the hepatic and extra-hepatic features of liver disease. In this review, we will discuss the current rodent models of liver injuries. We will then focus on the available ways to target specifically particular compounds of fibrogenesis and on the new models of liver diseases like the humanized liver mouse model.

Keywords: Animal models; Cell tracking; Fibrosis; Hepatic stellate cell; Liver.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None

References

    1. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 2011;25:195–206. . - DOI - PMC - PubMed
    1. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838–851. . - DOI - PMC - PubMed
    1. Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology. 2009;50:1294–1306. . - DOI - PubMed
    1. Tsukamoto H, Matsuoka M, French SW. Experimental models of hepatic fibrosis: a review. Semin Liver Dis. 1990;10:56–65. . - DOI - PubMed
    1. Hooijmans CR, Leenaars M, Ritskes-Hoitinga M. A gold standard publication checklist to improve the quality of animal studies, to fully integrate the Three Rs, and to make systematic reviews more feasible. Altern Lab Anim. 2010;38:167–182. - PubMed